Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Survey and Trend Research 2018

December 2017 | 89 pages | ID: G3A0CA4C90BEN
99Strategy

Abstracts

SUMMARY

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

This report describes the development of the industry by upstream & downstream, industry overall and development, key companies, as well as type segment & market application and so on, and makes a scientific prediction for the development industry prospects on the basis of analysis, finally, analyzes opportunities for investment in the industry at the end of the report.

Industry Chain

• Raw Materials
• Cost
• Technology
• Consumer Preference

Industry Overall:

• History
• Development & Trend
• Market Competition
• Trade Overview
• Policy

Region (North America, Europe, Asia-Pacific, South America, Middle East, Africa):

• Regional Market
• Production Development
• Sales
• Regional Trade
• Regional Forecast

Company (Novo Nordisk, AstraZeneca, Eli Lily, GSK, Bristol-Myers Squibb, Bristol-Myers Squibb, Amylin etc.):

• Company Profile
• Product & Service
• Business Operation Data
• Market Share

Investment Analysis:

• Market Features
• Investment Opportunity
• Investment Calculation

Contents

PART 1 INDUSTRY OVERVIEW

1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry
  1.1.1 Definition
  1.1.2 Industry Trend
1.2 Industry Chain
  1.2.1 Upstream
  1.2.2 Technology
  1.2.3 Cost Structure
  1.2.4 Consumer Preference
  1.2.2 Downstream

PART 2 INDUSTRY OVERALL

2.1 Industry History
2.2 Development Prospect
2.3 Competition Structure
2.4 Relevant Policy
2.5 Trade Overview

PART 3 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY PRODUCT

3.1 Products List of Major Companies
3.2 Market Size
3.3 Market Forecast

4 KEY COMPANIES LIST

4.1 Novo Nordisk (Company Overview, Sales Data etc.)
  4.1.1 Company Overview
  4.1.2 Products and Services
  4.1.3 Business Analysis
4.2 AstraZeneca (Company Overview, Sales Data etc.)
  4.2.1 Company Overview
  4.2.2 Products and Services
  4.2.3 Business Analysis
4.3 Eli Lily (Company Overview, Sales Data etc.)
  4.3.1 Company Overview
  4.3.2 Products and Services
  4.3.3 Business Analysis
4.4 GSK (Company Overview, Sales Data etc.)
  4.4.1 Company Overview
  4.4.2 Products and Services
  4.4.3 Business Analysis
4.5 Bristol-Myers Squibb (Company Overview, Sales Data etc.)
  4.5.1 Company Overview
  4.5.2 Products and Services
  4.5.3 Business Analysis
4.6 Bristol-Myers Squibb (Company Overview, Sales Data etc.)
  4.6.1 Company Overview
  4.6.2 Products and Services
  4.6.3 Business Analysis
4.7 Amylin (Company Overview, Sales Data etc.)
  4.7.1 Company Overview
  4.7.2 Products and Services
  4.7.3 Business Analysis

PART 5 MARKET COMPETITION

5.1 Companies Competition
5.2 Industry Competition Structure Analysis
  5.2.1 Rivalry
  5.2.2 Threat of New Entrants
  5.2.3 Substitutes
  5.2.4 Bargaining Power of Suppliers
  5.2.5 Bargaining Power of Buyers

PART 6 MARKET DEMAND BY SEGMENT

6.1 Demand Situation
  6.1.1 Industry Application Status
  6.1.2 Industry SWOT Analysis
    6.1.2.1 Strengths
    6.1.2.2 Weaknesses
    6.1.2.3 Opportunities
    6.1.2.4 Threats
6.2 Major Customer Survey
6.3 Demand Forecast

PART 7 REGION OPERATION

7.1 Regional Market
7.2 Production and Sales by Region
  7.2.1 Production
  7.2.2 Sales
  7.2.3 Trade
7.3 Regional Forecast

PART 8 MARKET INVESTMENT

8.1 Market Features
  8.1.1 Product Features
  8.1.2 Price Features
  8.1.3 Channel Features
  8.1.4 Purchasing Features
8.2 Investment Opportunity
  8.2.1 Regional Investment Opportunity
  8.2.2 Industry Investment Opportunity
8.3 Investment Calculation
  8.3.1 Cost Calculation
  8.3.2 Revenue Calculation
  8.3.3 Economic Performance Evaluation

PART 9 CONCLUSION

List Of Tables

LIST OF TABLES

Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2012-2017, by Type, in USD Million
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2012-2017, by Type, in Volume
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast 2018-2023, by Type, in USD Million
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast 2018-2023, by Type, in Volume
Table Novo Nordisk Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of Novo Nordisk (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table AstraZeneca Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of AstraZeneca (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Eli Lily Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of Eli Lily (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table GSK Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of GSK (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Bristol-Myers Squibb Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of Bristol-Myers Squibb (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Bristol-Myers Squibb Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of Bristol-Myers Squibb (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Amylin Overview List
Table Glucagon Like Peptide-1 (GLP-1) Agonists Business Operation of Amylin (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Revenue 2012-2017, by Companies, in USD Million
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Revenue Share, by Companies, in USD Million
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume 2012-2017, by Companies, in Volume
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Revenue Share, by Companies in 2017, in Volume
Table Glucagon Like Peptide-1 (GLP-1) Agonists Demand 2012-2017, by Application, in USD Million
Table Glucagon Like Peptide-1 (GLP-1) Agonists Demand 2012-2017, by Application, in Volume
Table Glucagon Like Peptide-1 (GLP-1) Agonists Demand Forecast 2018-2023, by Application, in USD Million
Table Glucagon Like Peptide-1 (GLP-1) Agonists Demand Forecast 2018-2023, by Application, in Volume
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2012-2017, by Region, in USD Million
Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2012-2017, by Region, in Volume
Table Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast 2018-2023, by Region, in USD Million
Table Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast 2018-2023, by Region, in Volume

List Of Figures

LIST OF FIGURES

Figure Glucagon Like Peptide-1 (GLP-1) Agonists Industry Chain Structure
Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2012-2017, by Type, in USD Million
Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2012-2017, by Type, in Volume
Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Revenue Share, by Companies in 2017, in USD Million
Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2012-2017, by Companies, in Volume
Figure Production Development by Region
Figure Sales List by Region